Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer
View More
Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials
View More
Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
2nd Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer
View More
Older Women with Breast Cancer Can Tolerate Surgery, But Often Pursue Other Treatment Options
November 6th 2020A study presented at the 12th European Breast Cancer Conference suggests women over the age of 70 with breast cancer can tolerate surgery even though they aren’t offered it regularly, but a second abstract suggests these women tend to opt out of this treatment option.
Beneficial, Cost-Effective Breast Cancer Therapy Not Offered to All Patients
October 29th 2020A study led by Jefferson researchers found that not all patients, specifically African American patients and women without private insurance, receive the same breast cancer treatment, specifically the beneficial and more cost-effective hypofractionated whole breast radiation therapy.
Combined Study Analysis Determines Best Drug Choices for Patients with Advanced Breast Cancer
October 21st 2020Detection of ESR1 mutations in baseline ctDNA was associated with inferior progression-free survival and overall survival in patients with advanced HR-positive breast cancer treated with exemestane versus fulvestrant.
Breast Cancer Incidence Rates Increase for Racial/Ethnic and Age Groups Between 2010 to 2016
October 19th 2020A recent examination of breast cancer subtypes, specifically luminal A and luminal B breast cancer, found that incidence rates from 2010-2016 increased for a number of racial/ethnic and age groups.
Phase 3 PENELOPE-B Trial Fails to Meet Meet Primary End Point for HR+, HER2- Early Breast Cancer
October 9th 2020The trial did not meet its primary end point of improved invasive disease-free survival in women with hormone receptor-positive HER2-negative early breast cancer who have residual invasive disease after completing neoadjuvant chemotherapy.
FDA Issues Alert for Atezolizumab, Paclitaxel Combination in Patients with TNBC
September 9th 2020The agency indicated that the use of atezolizumab (Tecentriq) and paclitaxel in patients with previously untreated, inoperable, locally advanced, or metastatic triple negative breast cancer was not effective in treating the disease.
Pinpointing Independent Prognostic Factors Related to Treatment Modality in Breast Cancer
August 22nd 2020Researchers indicated that these study findings could set a basis to pinpoint independent prognostic factors related to a treatment modality in patients with breast cancer and provide clarity for the assessment of surrogate markers for overall survival.
Overweight, Obese Patients with Breast Cancer May Benefit Less from Docetaxel Treatment
August 14th 2020Though the results still need to be confirmed, researchers suggested these findings indicate a need to better understand how BMI affects the biology, progression, and treatment efficacy of breast cancer.
Phase 3 IMpassion131 Study Fails to Meet Primary End Point of PFS in Metastatic TNBC
August 7th 2020The study evaluating atezolizumab in combination with paclitaxel compared to placebo plus paclitaxel did not meet its primary end point of progression-free survival in patients with metastatic triple-negative breast cancer.